D&O Insurance is made up of 3 parts - Side A, B and C coverage. This 2 minute vidoe provides an overview of each and how they apply to claims.
If you haven’t heard Snap, better known as Snapchat, is being investigated for its disclosures leading up to its IPO in 2017. You can find a good overview at TheStreet about the ins and outs of the case, but here are the two major allegations: Snap withheld information regarding the level of competition it faced … Continue reading D&O Lessons From Snapchat
Last week the issue of public companies having to do quarterly reports popped up in the news in a big way with the President tweeting and then speaking on the possibility of ending quarterly reporting. There are a lot of opinions out there on whether this is a good idea or bad idea. Some people … Continue reading How Changing the Reporting Period for Public Companies to Semiannual Could Impact the D&O Market
Cornerstone Research always puts out great data and this report on Securities Class Action Filings for the first half of 2018 is no exception. I recommend you check out the full report which you can find here. These visuals really speak for themselves but the big takeaway is that if you are publicly traded company … Continue reading Why Securities Class Filings are a Reality for Publicly Traded Companies
It's a new week and this is what I'm reading to get going: While Tech Waffles On Going Public, Biotech IPOs Boom (Crunchbase) Smart Bandage Can Dispense Drugs, While Keeping An Eye On Your Wound (FORBES) Tendyne investors sue Abbott over $50m milestone (MassDevice). In case you missed, my thoughts on how a company can … Continue reading Monday Morning Healthcare News
Here is a collection of articles I have found both relevant and timely in respects to the life science and healthcare industry over the past week or so. There are 503 pages in the new tax law – 12 of those pages could dramatically impact the Private Equity sector (The American Prospect) Investment in Digital … Continue reading Articles of the Week
Good morning, here is what I'm reading today: And so it continues...Biopharma IPOs gone wild: Highest amount ever raised as 14 companies join public ranks (Clarivate) Not all news about Pfizer is about drug pricing, they will also be reorganizing into three distinct business units (BioPharma Dive). Not all money is being raised on the … Continue reading Thursday Morning Reads